By Elaine Rigoli
Tampa, Fla., Sept. 19 - Singulex, Inc. said Tuesday that it has raised $10.5 million in series C and debt-financing deals, has added Mickey Urdea to the board of directors and successfully completed several commercial pilot studies with research labs and pharmaceutical partners using the company's Zeptx system.
The pharmaceutical company also said it opened a 6,000-square-foot commercial operation facility in Hayward, Calif. Research and development efforts will remain at the company's facility at the St. Louis Center for Emerging Technologies.
Existing investors Fisk Venture and Prolog Ventures were part of the latest financing round totaling $8 million, which was led by a new undisclosed investor. The company also closed a $1 million financing round from GE Capital and $1.5 million debt financing from Bridge Bank, bringing the total amount raised to $10.5 million.
"Establishing normal protein levels has presented serious hurdles in the advancement of diagnostics for therapy selection, disease diagnosis and preclinical and clinical evaluation of therapeutic candidates. The Zeptx system is engineered to enable life-science researchers to obtain quantitative information on normal and abnormal protein levels in any type of biological sample," said Philippe Goix, chief executive officer and president, in a statement.
| Issuer: | Singulex, Inc.
|
| Issue: | Series C financing, debt financing
|
| Amount: | $10.5 million
|
| Investors: | Fisk Venture, Prolog Ventures, undisclosed investor, GE Capital, Bridge Bank
|
| Announcement date: | Sept. 19
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
